Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Interactions between drugs can also be measured at lowest doses

11.04.2013
Interaction at minimal dose identical to therapeutically effective dose / Pharmacological studies becoming more reliable / Study published in Clinical Pharmacology & Therapeutics

Clinical pharmacologists at Heidelberg University Hospital have achieved major progress for improving the reliability of drugs. In a pharmacological study, they showed for the first time that interactions between drugs can be detected with minute doses in the range of nanograms.

However, at these low doses, the drugs are neither effective nor do they have side effects. This means that studies on interactions occurring in drug combinations can be conducted practically without posing risks or negative impacts on the participants. This is true not only for healthy volunteers, as has been observed to date, but also for patients. The study was published in the medical journal Clinical Pharmacology & Therapeutics.

“Many chronically ill or elderly patients today take several different drugs. Around two percent of all hospital stays in Germany are the result of interactions between the drugs,” said Professor Walter E. Haefeli, Medical Director of the Department for Clinical Pharmacology and Pharmacoepidemiology at Heidelberg University, where the new technique of “nano-dosing” has been developed and tested. “Many interactions could be avoided if we were aware of them and took them into account.”
Drug combinations rarely studied for interactions

However, very few drug combinations have been systematically tested for interactions to date. “Many risks remain unknown to date and need to be studied,” Prof. Haefeli explained. After initial tests conducted in animals, combinations are currentlybeing studied in healthy participants – with the usual therapeutic doses. Depending on the drug, this can strongly impact the body. Furthermore, a healthy person may react differently to a drug than a sick person does. This means that study findings can only be transferred to a limited extent.

Using mass spectrometry, an ultrasensitive technique, the team led by Prof. Haefeli succeeded in drastically reducing the dose for studies on interactions in study participants. Mass spectrometers are so sensitive that they are able to identify the drug in a single drop of blood. The scientists conducted a study on interactions in 12 healthy test persons taking the fungicide ketoconazole and the sedative midazolam simultaneously. For the study, they administered midazolamdoses of 0.0000001 g, which was 30,000 times lower than the amount used for therapy. Comparisons with higher doses revealed that the drugs behaved identically at all concentrations. Therefore, even a minimal concentration in the body is sufficient to reliably predict the extent of the interaction during normal use.
Inhibition of the liver enzyme measurable in the nanogram range

With the help of ultrasensitive mass spectrometers, the speed with which a drug is degraded can be measured. They are used wherever small amounts need to be detected in liquids, e.g., contamination in drinking water, doping agents or environmental toxins. To this end, a small amount of blood or other body fluid is withdrawn after certain time intervals in order to determine the remaining concentration of the drug. The mass spectrometer sorts the molecules and determines their concentration. Based on their characteristic properties, the drugs can be reliably identified. “For the first time, we have proven that with this technique, we are able to find drugs in the blood even at extremely low doses, and that we can quantitatively determine them and identify their interactions,” Prof. Haefeli said.

In the published study, the team investigated the interaction between the sedative midazolam, which is metabolized in the liver by the protein cytochrome P450 3A, and the fungicide ketoconazole, a well-known inhibitor of this cytochrome. The inhibition of the cytochrome and, in turn, the reduced degradation of midazolam, were already precisely measured in the nanogram dose. This interaction in particular plays an important role for patients who need to take several drugs simultaneously. Many drugs inhibit this enzyme, which metabolises around half of all regularly used medicines. However, if a drug is degraded too slowly, at normal doses, it accumulates in the body and, in the worst case, can cause toxicity.

Further studies planned

Prof. Haefeli and his team are now testing the new method in patients. “Since we can use minimal drug doses, these studies are also safe for patients,” Prof. Haefeli explained. Heidelberg University pharmacologists will also examine the interactions of other medications that influence other metabolic enzymes. “The method could also be used in the many studies in which interactions are relevant for approval by the authorities, for instance,” said Prof. Haefeli, looking toward the future.

Literature:
Burhenne J, Halama B, Maurer M, Riedel K-D, Hohmann N, Mikus G, Haefeli WE: Quantification of femtomolar concentrations of the CYP3A substrate midazolam and its main metabolite 1’-hydroxymidazolam in human plasma using ultra-performance liquid chromatography coupled to tandem mass spectrometry. Anal Bioanal Chem 2012;402:2439-50.

Halama B, Hohmann N, Burhenne J, Weiss J, Mikus G, Haefeli WE: A nanogram dose of the CYP3A probe substrate midazolam to evaluate drug interactions. Clin Pharmacol Ther; accepted article preview online February 8, 2013; doi:10.1038/clpt.2013.
More information is available on the web:
Dept. of Clinical Pharmacology and Pharmacoepidemiology:
http://www.klinikum.uni-heidelberg.de/index.php?id=117526&L=1

Contact:
Prof. Walter E. Haefeli, MD
Head of Dept. of Clinical Pharmacology and Pharmacoepidemiology
phone: +49 6221 56 8740
email: walter.emil.haefeli@med.uni-heidelberg.de

Heidelberg University Hospital and Medical Faculty:
Internationally recognized patient care, research, and teaching
Heidelberg University Hospital is one of the largest and most prestigious medical centers in Germany. The Medical Faculty of Heidelberg University belongs to the internationally most renowned biomedical research institutions in Europe. Both institutions have the common goal of developing new therapies and implementing them rapidly for patients. With about 11,000 employees, training and qualification is an important issue. Every year, around 510,000 patients are treated on an inpatient or outpatient basis in more than 50 clinics and departments with 1,900 beds. Currently, about 3,500 future physicians are studying in Heidelberg; the reform Heidelberg Curriculum Medicinale (HeiCuMed) is one of the top medical training programs in Germany.

Requests by journalists:
Dr. Annette Tuffs
Director, Corporate Communication/Public Relations
University Hospital and
Medical Faculty of Heidelberg
Im Neuenheimer Feld 672
69120 Heidelberg
Germany
phone: +49 6221 / 56 45 36
fax: +49 6221 / 56 45 44
e-mail: annette.tuffs@med.uni-heidelberg.de

Selected english press releases online:
http://www.klinikum.uni-heidelberg.de/presse

Dr. Annette Tuffs | idw
Further information:
http://www.uni-heidelberg.de

More articles from Health and Medicine:

nachricht New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia

nachricht New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Fizzy soda water could be key to clean manufacture of flat wonder material: Graphene

Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.

As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...

Im Focus: Exotic quantum states made from light: Physicists create optical “wells” for a super-photon

Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.

Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...

Im Focus: Circular RNA linked to brain function

For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.

While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...

Im Focus: RAVAN CubeSat measures Earth's outgoing energy

An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.

The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...

Im Focus: Scientists shine new light on the “other high temperature superconductor”

A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.

Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Call for Papers – ICNFT 2018, 5th International Conference on New Forming Technology

16.08.2017 | Event News

Sustainability is the business model of tomorrow

04.08.2017 | Event News

Clash of Realities 2017: Registration now open. International Conference at TH Köln

26.07.2017 | Event News

 
Latest News

A Map of the Cell’s Power Station

18.08.2017 | Life Sciences

Engineering team images tiny quasicrystals as they form

18.08.2017 | Physics and Astronomy

Researchers printed graphene-like materials with inkjet

18.08.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>